A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells

• Published in: Cellular oncology (Dordrecht) 2024-10, Vol.47 (5), p.1879-1895
• Main Authors: Yan, Zhifeng, Gu, Runxia, Ma, Haotian, Chen, Nianci, Zhang, Ting, Xu, Yingxi, Qiu, Shaowei, Xing, Haiyan, Tang, Kejing, Tian, Zheng, Rao, Qing, Wang, Min, Wang, Jianxiang
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Bispecific - immunology; Antibodies, Bispecific - pharmacology; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cell Line, Tumor; Cytotoxicity, Immunologic; Humans; Immunotherapy, Adoptive - methods; Leukemia, Myeloid, Acute - immunology; Leukemia, Myeloid, Acute - therapy; Mice; Mice, Inbred NOD; Oncology; Pathology; Receptors, Chimeric Antigen - immunology; Receptors, Interleukin-10 - immunology; Sialic Acid Binding Ig-like Lectin 3 - immunology; T-Lymphocytes - immunology; Xenograft Model Antitumor Assays
• ISSN: 2211-3428; 2211-3436; 2211-3436
• DOI: 10.1007/s13402-024-00971-5

Background Immunotherapies, including chimeric antigen receptor (CAR) T cells and bispecific antibodies (BsAbs), encounter several challenges in the management of acute myeloid leukemia (AML), including limited persistence of these treatments, antigen loss and resistance of leukemia stem cells (LSCs) to therapy. Methods Here, we proposed a novel dual-targeting approach utilizing engineered anti-IL10R CAR-T cells to secrete bispecific antibodies targeting CD33. This innovative strategy, rooted in our previous research which established a connection between IL-10 and the stemness of AML cells, designed to improve targeting efficiency and eradicate both LSCs and AML blasts. Results We first demonstrated the superior efficacy of this synergistic approach in eliminating AML cell lines and primary cells expressing different levels of the target antigens, even in cases of low CD33 or IL10R expression. Furthermore, the IL10R CAR-T cells that secret anti-CD33 bsAbs (CAR.BsAb-T), exhibited an enhanced activation and induction of cytotoxicity not only in IL10R CAR-T cells but also in bystander T cells, thereby more effectively targeting CD33-positive tumor cells. Our in vivo experiments provided additional evidence that CAR.BsAb-T cells could efficiently redirect T cells, reduce tumor burden, and demonstrate no significant toxicity. Additionally, delivering bsAbs locally to the tumor sites through this strategy helps mitigate the pharmacokinetic challenges typically associated with the rapid clearance of prototypical bsAbs. Conclusions Overall, the engineering of a single-vector targeting IL10R CAR, which subsequently secretes CD33-targeted bsAb, addresses the issue of immune escape due to the heterogeneous expression of IL10R and CD33, and represents a promising progress in AML therapy aimed at improving treatment outcomes.